登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《 Pharmacological Res，3月4日，Traditional Chinese Medicine for COVID-19 Treatment》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-08

  • Traditional Chinese Medicine for COVID-19 Treatment

    Jun-lingRen, Ai-HuaZhang, Xi-JunWang

    Show more

    https://doi.org/10.1016/j.phrs.2020.104743

    Summary

    The current 2019-nCoV outbreak is moving rapidly [1], the cumulative number of confirmed cases in mainland China has reached 80151, with 47204 (58.89%) cured cases and 2943 (3.67%) deaths as of 2-Mar-2020, and no specific drug has been discovered for Coronavirus Disease 2019 (COVID-19). However, a number of clinical practice results showed that traditional Chinese medicine (TCM) plays significant role in the treatment of COVID-19, bringing new hope for the prevention and control of COVID-19.

  • 原文来源：https://www.sciencedirect.com/science/article/pii/S1043661820307556
78浏览量
原文链接
相关报告

  • 《SSRN，3月4日，Clinical Features and Treatment of 221 Patients with COVID-19 in Wuhan, China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-05
    • Clinical Features and Treatment of 221 Patients with COVID-19 in Wuhan, China 37 Pages Posted: 4 Mar 2020 Gu-qin Zhang Wuhan University - Department of Respiratory and Critical Care Medicine Chang Hu Wuhan University - Department of Critical Care Medicine Abstract Background: In late December 2019, an outbreak of acute respiratory illness, now officially named as COVID-19, or coronavirus disease 2019, emerged in Wuhan, China. We aimed to study the epidemiology and clinical features of patients diagnosed as coronavirus disease 2019 (COVID-19) and their treatment and outcome in Wuhan, China.
    124浏览量
    原文链接

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? – Authors' reply Peter J Richardson，Mario Corbellino，Justin Stebbing Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis. We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.
    93浏览量
    原文链接